A Phase 3 study evaluating bimekizumab for the treatment of psoriatic arthritis reached primary completion on 2026-05-26. The trial, which enrolled 1131 participants, aimed to assess the long-term safety, tolerability, and efficacy of the drug in adult subjects.
Background
The study investigated bimekizumab for adult subjects with psoriatic arthritis. This Phase 3 trial aimed to assess the long-term safety, long-term efficacy, and tolerability of bimekizumab administered subcutaneously in this patient population.
Trial design
The Phase 3 study (NCT04009499) enrolled 1131 adult participants with psoriatic arthritis. The trial's primary objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab. The study is now listed as COMPLETED on ClinicalTrials.gov.
What this means
The primary completion of this Phase 3 study indicates that data collection for the main objectives of the trial has concluded. While specific results are not yet available, this milestone brings the trial closer to potential data analysis and reporting on the long-term safety, tolerability, and efficacy of bimekizumab in individuals with psoriatic arthritis. Clinicians and patients will await the full results to understand the potential impact of bimekizumab in this population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event for study NCT04009499, titled "A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis", was recorded on 2026-05-26 on clinicaltrials.gov.